Congratulations to Mogrify Chair, Dr. Jane Osbourn OBE, on the Lifetime Achievement Award presented to her last night at the @CambridgeIndy Science and Technology Awards 2025.

Congratulations to Mogrify Founder Professor Jose Polo for his appointment as the new Scientific Head of EMBL Australia.

Mogrify CSO, Jonathan Appleby, is attending Advanced Therapies 2025 this week at the London ExCel. Reach out for a catch-up and to learn more about the advancement of the MOGRIFY® direct in vivo cellular reprogramming platform.

Connect with Mogrify CEO, Darrin Disley, @jpmorgan's Healthcare week next month to discuss the application and progression of the MOGRIFY® platform in driving novel in vivo reprogramming therapies for disease areas with high unmet clinical need.

Connect with Mogrify as we join other innovators from across the global #biotech community next week (November 18-21) as part of Europe's largest dedicated #lifesciences and #healthcare week.

RT @UniofAdelaide: Our award-winning director of the Adelaide Centre for Epigenetics, Professor Jose Maria Polo, has recently been elected….

Only 3-weeks until Mogrify CEO, @DarrinMDisley, will be joining many of the biopharma community at the Biotechnology Innovation Organization's International Convention 2024, June 3-6, in San Diego.

In a recently published study, members of the Mogrify team used single nuclei RNA sequencing on healthy human limbal tissue to define the transcriptomes of the cell sub-populations within the human limbus.

We’re once again looking forward to joining the biopharma community at #JPM2024. Get the latest updates from the team across the MOGRIFY® direct reprogramming platform and anticipated therapeutic program milestones over the next 6-12 months.

Talking about Mogrify’s novel class of in vivo reprogramming therapies and outlining key milestones to look out for in the next 12 months, Mogrify CEO, Dr. Darrin Disley caught up with @LongevityTech following the Company's recent Series A extension.

Great to catch up with biotech colleagues and the investment community at yesterday's @LSXLeaders Inv€$tival - here's Dr. Aida Moreno-Moral, Director of Cell Informatics, summarizing how MOGRIFY® enables novel in vivo reprogramming therapies.

Thank you to for featuring Mogrify in its top private investments round-up for biotech companies in October 2023.

Attending @LSXLeaders Inv€$tival Showcase? Join Aida Moreno-Moral at the TECHBIO stage (10:30am) to hear how MOGRIFY® uniquely enables our pipeline of in vivo reprogramming therapies and what to expect from the team over the coming months.

We’re excited to welcome Dr. Alun Barnard to the team as Dir. Ophthalmology, Alun joins us from Oxford Biomedica having spent three years working across cell and gene therapy program strategy as well as the design, initiation, and management of a range of preclinical studies.

We’re pleased announce an additional $10M USD closing of our Series A financing, bringing the total raised to $46M USD in this round. Funding will support advancement of our pipeline of #invivoreprogramming therapies through pre-clinical translation.

New follower? Learn more about Mogrify's proprietary suite of platform technologies capable of systematically identify the key transcriptomic and epigenetic switches required to drive direct cellular reprogramming. .

Attending the @_BSGCT Annual Conference this week? Join Snr. Dir. R&D, David Matthews, and the team who will be discussing the translation of advanced therapies, as well as Mogrify’s novel class of in vivo reprogramming therapies.

Presented at last week's @ISSCR Annual Meeting, Mogrify SAB member, Prof. Christine Mummery receives the 2023 ISSCR Public Service Award for outstanding contributions of public service to the fields of #stemcell research and #regenerativemedicine.

Mogrify is making real and impactful changes to decrease the environmental footprint of our research and has been awarded the highest level 'Green' status in the #MyGreenLabCertification Program run by non profit @My_Green_Lab.

Taking part in the #ASCGT23 Meeting? Join Snr. Director of R&D, David Matthews, who will be diving deep into the latest from the field of cell and gene therapy, as well as discussing our novel class of in vivo reprogramming therapies. Get in touch:.